BNET Industries
Savient Pharmaceuticals Inc. (SVNT) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $14.0M
- Profit
- Dec 31 2007
- ($48.6M)
- Market Cap
- Nov 28 2008
- $201.2M
Latest News and Analysis
Earnings Preview: Savient Pharmaceuticals
Savient Pharmaceuticals SVNT is expected to report Q3 earnings after market close Wednesday Nov. 5, with a conference call scheduled for Thursday, November 6 at 10:00 am ET. Guidance Analysts are expecting a loss of (39c) on revenue of $600K. The consensus range for EPS is (42c) to (35c) with...
Tuesday Options Outlook: LEH, WM, AIG, OIH, DOX, TRA, SVNT
Rebecca Engmann Darst co-authored this article. Lehman Brothers LEH – Traders lost patience with still-fruitless talks between Lehman Brothers and Korea Development Bank, and a concomitant increase in the price of credit default protection appeared to be all it took to send implied volatility up some 88% as shares tanked...
Savient Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator [Operator instructions]. And your first question is from Leland Gershell from Cowen and Company. Leland Gershell Hi, good morning. Thanks for taking my questions. With those seven patients treated with a dose in the re-exposure trial, any safety observations you can share with us from those...
Savient Pharmaceuticals, Inc. Q4 2007 Earning Call Transcript
Question-and-Answer SessionOperator Operator Instructions. Your first question will come from the line of Leland Gershell with Cowen & Company. Leland Gershell Good morning. Thanks for the update and for taking my questions. I was wondering, first question you had mentioned previously the intention to conduct re-treatment...
Savient to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Christopher G. Clement, President and Chief Executive Officer, and Zeb Horowitz M.D., Chief Medical Officer of Savient Pharmaceuticals, will present a corporate update at the upcoming 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference that will...
Savient Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that Christopher G. Clement, President and Chief Executive Officer and Zeb Horowitz M.D., Chief Medical Officer of Savient Pharmaceuticals will present a corporate update at the upcoming 26th Annual JP Morgan Healthcare Conference. The presentation is scheduled for 4:00...
Savient Pharmaceuticals Q3 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions Your first question will come from the line of Leland Gershell with Cowen & Company. Leland Gershell - Cowen & Company Hi, thanks for taking the question. First question is on trial dropouts and powering, you had mentioned a 155 patients completed the Phase III...
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism 2007 Annual Congress
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that two abstracts exploring Phase 2 Puricase([R]) (PEG-uricase) data and quality of life in treatment-failure gout patients will be presented at the European League Against Rheumatism EULAR 2007 Annual Congress taking place June 13 - 16th in Barcelona, Spain....
ROTH New York Conference 2006 Presenter Profiles
NEW YORK -- ROTH New York Conference 2006 takes place September 6-7, 2006 at the Westin New York at Times Square. For in-depth information about the event, please visit http://www.rothconference.com/ . Below are profiles from ROTH New York Conference 2006 presenters. Breaking news releases are available at http://www.tradeshownews.com and...
Four Abstracts Accepted for Savient's Puricase® at European League Against Rheumatism 2006 Annual Congress
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc., (NASDAQ: SVNT) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that four abstracts further detailing data on the Phase 2 clinical trial results of its drug development candidate, PuricaseR (PEG-uricase), and...
Savient's Puricase(R) (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients With Treatment-Resistant Gout.
SAN DIEGO, November 21 /PRNewswire/ -- - Anecdotal Evidence Shows Resolution of Tophi - Phase 2 Data Presented at the 2005 Annual Meeting of the American College of Rheumatology Savient Pharmaceuticals, Inc. (Nasdaq: SVNTE) announced that patients with elevated blood uric...
Savient Pharmaceuticals Provides Business Update; Financial Overview and Recent Strategic Developments
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc., (NASDAQ: SVNTE) an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, today provides a business and financial overview for the quarter ended September 30, 2005. Savient announced on...
Savient Pharmaceuticals Receives Filing Extension from Nasdaq
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE), an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that the Nasdaq Listing Qualifications Panel (the "Panel") has agreed to continue the listing of the Company's securities on The Nasdaq...
Savient Pharmaceuticals Determines Periods Affected for Restatement Include Six Months Ended June 30, 2005 and Fiscal Years Ended 2004, 2003 and 2002
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that the Company's Audit Committee, with the assistance of management, counsel and independent accounting consultants, and as discussed with its independent...
Savient Audit Committee Completes Review
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that its Audit Committee has completed its review and investigation, with the assistance of management, counsel and independent accounting consultants, of...
Savient Pharmaceuticals, Inc. to Present at the Banc of America Securities 2005 Specialty Pharmaceuticals Conference
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, today announced that Christopher Clement, President and Chief Executive Officer and Dr. Zeb Horowitz, Senior Vice President and Chief Medical Officer will present at...
U.S. BioDefense plans stem cell IPO, Savient Pharmaceuticals, Inc. to present at the UBS 2005 Global Life Sciences Conference.
M2 PRESSWIRE-23 May 2005-US Financial Network: U.S. BioDefense plans stem cell IPO, Savient Pharmaceuticals, Inc. to present at the UBS 2005 Global Life Sciences ConferenceC1994-2005 M2 COMMUNICATIONS LTD RDATE:23052005 City of Industry, CA - Biotechnology industry news provided by Financial News...
"Stocks on the Rise".
M2 PRESSWIRE-13 May 2005-WallStreetGrapevine: "Stocks on the Rise"C1994-2005 M2 COMMUNICATIONS LTD RDATE:13052005 Wall Street, NYC -Today, wallstreetgrapevine.com, named; Bio-Matrix Scientific Group Inc. (Pink Sheets: BMXG), Large Scale Biology Corp. (Nasdaq NM: LSBC), Chiron Corporation (Nasdaq NM: CHIR), and Savient Pharmaceuticals...
Savient Pharmaceuticals, Inc. to be Added to NASDAQ Biotechnology Index
Business Editors/Health/Medical Writers BIOWIRE2K EAST BRUNSWICK, N.J.--BUSINESS WIRE--Nov. 14, 2003 Savient Pharmaceuticals, Inc. Savient, (NASDAQ:SVNT), today announced that the Company will be added to the NASDAQ Biotechnology Index NBI effective Monday, November 24, 2003. All securities in the Index are listed on the NASDAQ National Market and...
Additional Resources
Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Savient Pharmaceuticals, Inc. (NASDAQ: SVNT)
On November 25, 2008, a class actionlawsuit was filed in the United States District Court for the SouthernDistrict of New York against Savient Pharmaceuticals, Inc. (NASDAQ: SVNT).The complaint alleges violations of federal securities laws, Sections 10band 20a of the Securities Exchange Act of 1934 and Rule 10b-5, includingallegations of issuing...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Incorporated: 1980
- CEO: Mr. Paul Hamelin
Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs. At Dec 31 2007, Co. sold and distributed OxandrinŽ, the branded version of its oxandrolone that is used to promote weight gain following involuntary weight loss, and distributed the generic version of its oxandrolone through an agreement with Watson Pharmaceuticals, Inc. Co. is also developing PuricaseŽ, for the control of uric acid in patients with gout whose signs and symptoms are inadequately controlled by conventional urate lowering therapy due to ineffectiveness, dose limiting toxicity, hypersensitivity or other contraindications.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
Savient Pharmaceuticals Inc. Company Info
Board of Directors
Mr. Herbert Conrad
Mr. Alan L. Heller
Mr. Joseph Klein III
Dr. Lee S. Simon M.D.
Mr. Virgil Thompson
Contact Information
One Tower Center, 14th Floor
East Brunswick, NJ
732 418-9300
NAICS Code
Medicinal and Botanical Manufacturing: 325411
